Key result
Vaccination with the recombinant rMDV-S1 virus significantly reduced morbidity (30% vs 100%) and mortality (5% vs 30%) in specific pathogen-free chickens challenged with QX-like infectious bronchitis virus compared to mock vaccination.
Why the study?
Does rMDV-S1 protect specific pathogen-free chickens against QX-like IBV and virulent MDV?
Does rMDV-S1 protect specific pathogen-free chickens against QX-like IBV and virulent MDV?
Absolute Event Rate: 30% vs 100%
p-value: p=<0.05
rMDV-S1 is an effective recombinant vaccine for preventing QX-like IBV and virulent MDV infections in chickens.
No takes yet. Share an insight, caveat, or question.
Supports recombinant MDV-based vaccines in poultry; leaves open field efficacy and commercial translation.
Zhang et al. (2012) studied Infectious bronchitis virus (IBV) and Marek's disease virus (MDV) infection (n=130). rMDV-S1 vaccine vs. CVI988/Rispens vaccine or PBS (mock) was evaluated on Morbidity after challenge with IBV CK/CH/JS/06II strain (p=<0.05). Vaccination with the recombinant rMDV-S1 virus significantly reduced morbidity (30% vs 100%) and mortality (5% vs 30%) in specific pathogen-free chickens challenged with QX-like infectious bronchitis virus compared to mock vaccination.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: